Antiproliferative Effect of Above-Label Doses of Somatostatin Analogues (SSA) for the Management of Neuroendocrine Tumors (NETs)

#2055

Introduction: Escalated doses of SSA have been used for control of refractory symptoms and tumour growth

Aim(s): However, there is limited evidence for the antiproliferative effect of this strategy

Materials and methods: Progression-free survival(PFS) was assessed in a large cohort of 116 patients on 3-weekly SSAs(as monotherapy).All patients were previously on maximum doses of SSAs every 4 weeks.Univariate(UVA) and multivariate(MVA) analyses were performed to identify factors affecting PFS

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Laskaratos F, Shah R, Banks J, Smith J, Jacobs B,

Keywords: above-label somatostatin analogues, neuroendocrine tumor,